Compounds > chitosan
Page last updated: 2024-08-25

chitosan and Anthrax

chitosan has been researched along with Anthrax in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80

Authors

AuthorsStudies
Chen, CC; Chen, XA; Cheng, KM; Chuang, CC; Kau, JH; Lee, CY; Shyu, HF; Tsai, MH; Yen, HJ; Young, JJ1
Agrawal, U; Jain, AK; Mangal, S; Pawar, D; Vyas, SP1
Chen, X; Liu, Y; Ma, G; Wang, L; Xu, J; Yang, X; Yin, Y; Zhang, W1
Bento, D; Borges, O; Gonçalves, T; Staats, HF1
Cheff, A; Hinchcliffe, M; Petrie, CR; Richardson, C; Stenz, JP; Tino, WT; Warwood, SJ; Williams, MS; Wimer-Mackin, S1

Other Studies

5 other study(ies) available for chitosan and Anthrax

ArticleYear
Nanoparticles assembled from fucoidan and trimethylchitosan as anthrax vaccine adjuvant: In vitro and in vivo efficacy in comparison to CpG.
    Carbohydrate polymers, 2020, May-15, Volume: 236

    Topics: A549 Cells; Adjuvants, Immunologic; Animals; Anthrax; Anthrax Vaccines; Bacillus anthracis; Chitosan; Cytokines; Female; Humans; Mice; Nanoparticles; Oligodeoxyribonucleotides; Polysaccharides

2020
Evaluation of mucoadhesive carrier adjuvant: toward an oral anthrax vaccine.
    Artificial cells, nanomedicine, and biotechnology, 2014, Volume: 42, Issue:1

    Topics: Adjuvants, Immunologic; Administration, Oral; Alginates; Animals; Anthrax; Anthrax Vaccines; Antibodies, Bacterial; Antigens, Bacterial; Bacillus anthracis; Bacterial Toxins; Biomimetic Materials; Chitosan; Female; Gastric Juice; Immunity, Innate; Immunity, Mucosal; Mice; Mice, Inbred BALB C; Neutralization Tests; Peyer's Patches; Vaccination

2014
Engineering biomaterial-associated complement activation to improve vaccine efficacy.
    Biomacromolecules, 2013, Sep-09, Volume: 14, Issue:9

    Topics: Adjuvants, Immunologic; Animals; Anthrax; Antibody Formation; Cell Proliferation; Cells, Cultured; Chitosan; Complement Activation; Cytokines; Female; Humans; Mice; Mice, Inbred BALB C; Microspheres; Particle Size; Surface Properties; T-Lymphocytes; Vaccine Potency

2013
Development of a novel adjuvanted nasal vaccine: C48/80 associated with chitosan nanoparticles as a path to enhance mucosal immunity.
    European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2015, Volume: 93

    Topics: Adjuvants, Immunologic; Administration, Intranasal; Alginates; Animals; Anthrax; Anthrax Vaccines; Antibodies, Bacterial; Antigens, Bacterial; Bacterial Toxins; Biomarkers; Chemistry, Pharmaceutical; Chitosan; Dose-Response Relationship, Drug; Drug Carriers; Female; Glucuronic Acid; Hexuronic Acids; Humans; Immunity, Mucosal; Immunization; Mast Cells; Mice; Mice, Inbred C57BL; Nanomedicine; Nanoparticles; Nasal Mucosa; p-Methoxy-N-methylphenethylamine; Particle Size; RAW 264.7 Cells; Surface Properties; T-Lymphocytes, Helper-Inducer; Technology, Pharmaceutical; Time Factors

2015
An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits.
    Vaccine, 2006, May-01, Volume: 24, Issue:18

    Topics: Adjuvants, Immunologic; Administration, Intranasal; Aerosols; Animals; Anorexia; Anthrax; Anthrax Vaccines; Antibodies, Bacterial; Antigens, Bacterial; Bacillus anthracis; Bacterial Capsules; Bacterial Toxins; Chitosan; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Female; Immunoglobulin G; Inhalation Exposure; Lipid A; Neutralization Tests; Polyglutamic Acid; Rabbits; Recombinant Fusion Proteins

2006